(Q80290141)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17488140%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

title

Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17488140%20AND%20SRC:MED&resulttype=core&format=json

cost-effectiveness analysis

30 December 2019

main subject

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17488140%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Michael J Millward

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17488140%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17488140%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17488140%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17488140%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17488140%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

429-442

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17488140%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00019053-200725050-00006

30 December 2019

exact match

0 references

cites work

Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?

1 reference

12 December 2020

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

12 December 2020

An economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial

1 reference

12 December 2020

When patients with breast cancer can be considered to be cured

1 reference

12 December 2020

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

1 reference

12 December 2020

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

12 December 2020

Factors influencing the effect of age on prognosis in breast cancer: population based study

1 reference

12 December 2020

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

12 December 2020

Are patients diagnosed with breast cancer before age 50 years ever cured?

1 reference

12 December 2020

Changes in long term prognosis for breast cancer in a Dutch cancer registry

1 reference

12 December 2020

Do estimates of long-term survival tell us whether patients diagnosed with breast cancer before age 50 years are ever cured?

1 reference

12 December 2020

Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials

1 reference

12 December 2020

Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Systematic overview of cost-utility assessments in oncology

1 reference

12 December 2020

Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year resu

1 reference

12 December 2020

A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis.

1 reference

12 December 2020

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer

1 reference

12 December 2020

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

12 December 2020